Saliva as a testing sample for SARS-CoV-2 1

detection by RT-PCR in low prevalence 2

3 community settings

- Didzis Gavars¹, Mikus Gavars¹, Dmitry Perminov^{1,4}, Janis Stasulans¹, 4
- 5 Justine Stana¹, Zane Metla¹, Jana Pavare³, Eriks Tauckels¹, Egils
- 6 Gulbis¹, Uga Dumpis^{2,4}
- 7 1 - E.Gulbja Laboratory, Riga, Latvia
- 8 2 - Pauls Stradins Clinical University Hospital, Riga Latvia
- 3 Children's Clinical University Hospital, Riga Stradins University, 9
- 10 Riga, Latvia
- 4 University of Latvia, Riga, Latvia 11

12 **Corresponding author:**

- 13 Dr. Didzis Gavars, E.Gulbja Laboratory
- Brivibas str.366, Riga, Latvia, LV-1006 14
- email: didzis@egl.lv; 15
- 16 telephone: +37129259742; fax: +37167543867

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract

18 **Objectives**

The number of COVID-19 cases is increasing globally and there is an
urgency for a simple non-invasive method for the detection of SARSCoV-2. Our study aimed to demonstrate that saliva can be used as a
specimen for SARS-CoV-2 detection notably for the screening of
extensive population groups via pooling.

24 Methods

To demonstrate that saliva is an appropriate specimen for SARS-CoV-25 2 detection a field study including 3,660 participants was performed 26 27 between September 29 and October 1, 2020. We collected paired nasopharyngeal/oropharyngeal swabs (NPS) and saliva specimens and 28 29 processed them within 24 hours of collection. We performed 36 serial measurements of 8 SARS-CoV-2 positive saliva samples to confirm 30 31 the stability of the specimen and completed 37 pools of saliva samples 32 by adding one positive specimen per pool.

33 Results

34 Saliva specimens were stable for testing for up to 24 hours. Overall, 35 44 salival samples (1.2%) tested positive for SARS-CoV-2 during the field study. The results of saliva samples were consistent with those 36 37 obtained from NPS from the same patient with 90% sensitivity (95% CI 68.3%-98.7%) and 100% specificity during the first two weeks after 38 39 the onset of symptoms. Using pooling strategy 796 RT-PCR tests were performed. All pools showed 100% positivity in different pooling 40 41 proportions.

42 Conclusions

Our findings demonstrate that saliva is an appropriate specimen for 43 44 pooling and SARS-CoV-2 screening with accurate diagnostic 45 performance. Patient-performed simple specimen collection allows 46 testing an extensive number of people rapidly, obtaining results of the spread of SARS-CoV-2 and allowing authorities to take timely 47 48 measures.

49

50 Introduction

Since the beginning of 2020 massive resources have been dedicated to 51 control and mitigate the COVID-19 pandemic. Testing capacity and 52 53 accessibility are crucial in monitoring COVID-19 outbreaks and allowing for the adjustment of measures put into place to reduce 54 55 community transmission (1).

56 Viral nucleic acid detection using the real-time polymerase chain 57 reaction (RT-PCR) assay remains the gold standard for the detection 58 of SARS-CoV-2 and to diagnose COVID-19 (2). Due to the increased demand for sampling and testing materials globally considerable 59 constraints remain to conduct widespread screening for SARS-CoV-2. 60 61 It is especially challenging for counties with low prevalence levels as 62 global suppliers allocate materials and decide delivery schedules based on the prevalence of the virus. 63

64 Shortages of supplies and medical staff, logistical hurdles, as well the 65 unpleasantness associated with obtaining a RT-PCR specimen making 66 it difficult to practice the procedure on children and causing irritation 67 for those who need to undergo repeated tests, all these factors have naturally accelerated research into alternative specimens and sampling 68 methods for COVID-19 testing (3,4). 69

On September 21, 2020, Latvia had a 14-day cumulative number of
COVID-19 cases of 5.1 per 100,000 people. By October 10 that
number had risen to 66. During this period, laboratories experienced a
significant overload (5). Rapid and efficient solutions to increase
testing capacity were needed.

The objective of this study was to confirm that saliva is a suitable specimen comparable to a nasopharyngeal/oropharyngeal swab for SARS-CoV-2 detection in specific populations. We also evaluated the pooling approach to employ it in field conditions for extensive screening of high-risk groups.

80

81 Methods

82 Patient sample collection

A single-center study was performed including all consented patients 83 attending the laboratory for SARS-CoV-2 testing between May 12 and 84 85 October 19, 2020. For the collection of the saliva samples, self-86 collection kits were distributed consisting of a specimen vial, 87 registration form, alcohol pads for disinfection, and two safety plastic 88 bags. Patients were requested to collect their saliva in an isolated 89 location (keeping at least five meters distance from other persons or 90 objects), preferably outdoors, at home, or in their car. The saliva was 91 collected in a container without any additive and delivered to the 92 laboratory within 24 hours. Paired nasopharyngeal/oropharyngeal 93 swabs (NPS) for RT-PCR were collected using the standard method 94 used in our laboratory (6).

95 Sample preparation and analysis using RT-PCR

96	Immediately upon arrival at the laboratory, the samples were
97	pretreated by adding 1 ml of phosphate-buffered saline (PBS). The
98	extraction of RNA and RT-PCR testing was identical for both swab
99	and pre-treated saliva samples. Viral RNA was extracted with standard
100	commercial extraction methods (QIAGEN, Germany and LifeRiver,
101	China) used in our laboratory. RT-PCR was performed using our
102	laboratory-developed and validated test method which detects S and N
103	genes of the SARS-CoV-2 virus. Our validated and verified limit of
104	detection (LOD) was 1 cp/rxn.

105

106 **Results**

107 Stability of saliva specimens

To confirm the stability of saliva samples, we performed 36 serial tests 108 109 on 8 primary SARS-CoV-2 positive saliva samples collected from 110 patients 48 hours after their NPS tested positive. The data are 111 summarized in Tables 1-3. Testing was randomized by different time 112 intervals, the time of day, and the shifts of technicians. It includes 113 repeated testing of two samples after 22h (Table 2) and serial repeats of one sample (Table 3) with Ct value reporting. 114

115 All results confirmed a positive result after 22-25h of the first test 116 being conducted. Samples were stored refrigerated at 2-6°C between 117 tests.

118 *Comparison of saliva and nasopharyngeal/oropharyngeal samples*

Between May 13 and September 21, 2020, 431 tests on saliva samples 119 were performed, and the results were compared with paired NPS RT-120 PCR test results. Using NPS RT-PCR as the reference, there were 121

104 PCR positive samples and 327 negative patients, including
125 pediatric (age 5-17 years (average 11.3 years)) samples. The
observed RT-PCR positive results were divided into groups according
to the number of days after the onset of symptoms: 0-14 days (22
patients); 15-30 days (52 patients); 31-70 days (20 patients) and
10 asymptomatic patients. The results of the comparison of the
mentioned subgroups are presented in Table 4.

129 Sensitivity and specificity for the respective groups were: for 0-14 days 90% (95%CI 68.3%-98.7%) and 100% (95%CI 22.4%-100%); 130 for 15-30 days 64.7% (95% CI 46.5%-80.3%) and 83.3% (95%CI 131 132 58.9%-96.4%); for 31-70 days 71.4% (95%CI 29.0%-96.3%) and 84.6% (95%CI 54.6%-98.1%); for asymptomatic 71.4% (95%CI 133 29.0%-96.3%) and 66.7% (95%CI 0.8%-90.6%). The mean Ct values 134 for the groups were 33.9 for NPS and 33.8 for saliva (0-14 days), 34.8 135 136 for NPS and 34 for saliva (15-30 days), and 36.5 for NPS and 39 for 137 saliva in the asymptomatic patient group.

138 Pooling of saliva

To evaluate the testing of pooled saliva samples, 37 pools were constituted. There were 15 pools of 5 samples (4 negatives + 1 positive), 13 pools of 10 samples (9 negatives + 1 positive), and 9 pools of 20 samples (19 negatives + 1 positive). The RT-PCR testing for each pool was repeated twice. The total number of measurements was 74. All results were 100% positive.

When using pooling, the number of tests needed per sample wascalculated as follows: the total number of tests needed to test allsamples is divided by the total number of samples. For example, if

> 148 500 samples are being tested in pools of 10, it means 50 tests are 149 initially needed. With a positivity rate of 1%, a maximum of five pools 150 will contain a positive specimen (if each positive sample is in a 151 different pool). The 50 samples from these five pools will have to be 152 retested individually (each of the five positive pools contains 10 153 samples). Therefore, a total of 100 tests are needed to evaluate all 154 500 samples and the number of tests per sample is 100/500 = 0.2.

155 The positivity rate in Latvia on September 23, 2020, was 0.5%.

156 The approximate positivity rate at which the pooling of 5 samples157 becomes more efficient than the pooling of 10 samples is 3% (2-4%)

158 depending on test price, laboratory load, tests per sample).

159 *Field study*

To evaluate the convenience of saliva pool testing by RT-PCR in field 160 161 conditions, the town of Kuldiga (total population 10,352) with an 162 ongoing outbreak of COVID-19 in a textile factory was selected. In 163 collaboration with local authorities, 4,100 saliva self-sampling kits 164 were distributed to inhabitants at a specially established distribution point. There were four persons dedicated to the distribution of the kits 165 and four drivers to deliver the samples by car to the testing laboratory 166 in Riga (150 km one way). During the study period, 3,660 saliva 167 samples were collected (response rate 91.5%), delivered to the 168 laboratory, and tested in pools of 10 samples. There were a total of 169 170 366 pools. In the first round of testing 43 pools were found to be 171 positive and samples from these pools were re-tested individually. The 172 saliva samples from 44 patients were confirmed as positive by RT-PCR. Mean Ct values of pooled samples were 13% higher than 173

individually tested Ct (31.6 versus 27.6). The positivity rate of the
tested population was 1.2%. In total 796 RT-PCR tests were
performed. At the time of the sample collection, 68.2% (30/44) of
patients did not report any symptoms on the questionnaire form.
Nasopharyngeal swab tests and saliva tests were compared with the

number of new COVID-19 cases. The findings illustrate that the
second peak in new cases occurred 6-7 days after the initial peak. Such
findings correspond with the mean incubation period of the SARSCoV-2. The results reflect a decrease in new cases in the following
observation period (Figure 1).

184

185 Discussion

186 The findings of our study can be summarized as follows: (a) for the 187 detection of SARS-CoV-2, saliva is a stable specimen with acceptable 188 specificity and sensitivity at the early stages of infection; (b) saliva 189 specimen is appropriate for pooling, with accurate diagnostic 190 performance.

191 Saliva has been identified as a reliable testing specimen for SARS-192 CoV-2 using the RT-PCR approach in several recent studies (7–9). In 193 the updated European Centre for Disease Prevention and Control (ECDC) recommendations, saliva is also mentioned as a convenient 194 specimen for SARS-CoV-2 testing (10,11). The FDA has approved 195 196 methods for SARS-CoV-2 testing using saliva in several laboratories 197 (12,13). Nevertheless, saliva has been included in IFCC COVID-19 Guidelines Serological, 198 on Molecular. and 199 Biochemical/Haematological Testing as a promising sample type (14).

> The high expression of ACE2 receptors in salivary gland cells is the main factor for virus affinity that could lead to active replication and transmission by saliva droplets expelled into the air during coughing or sneezing (15,16).

> It is essential to establish standardized sample collection procedures,
> safe logistics, and reliable testing methods that meet performance
> requirements. Our stability testing confirmed that saliva samples
> stayed equally positive up to 24h.

208 In the analytical context, saliva can have the same or even better 209 performance than NPS (17). It has been previously confirmed to be 210 highly sensitive and specific at the early stage of infection 0-14 days 211 after onset of symptoms and in asymptomatic cases (17,18). Therefore, 212 it is essential to take into consideration the relationship between the 213 dynamics of viral load, Ct values, and the number of days after the 214 onset of symptoms. As described in prior publications, the Ct value is 215 important in determining the infectiousness of a patient sample. Ct 216 values above 34 do not emit infectious virus particles, and values between 27-34 show low viability of the viral load. Samples with a Ct 217 218 value of 13-17 show positive virus viability (19). Ct values may vary depending on the different assays by up to 5 cycles for the same sample 219 (20). Variation also appears due to the quality of the specimen obtained 220 221 and the different treatment methods used to prepare samples for testing 222 (21). As expected, we got some variation between the NPS and saliva 223 sample types. In our pilot testing using 44 positive saliva samples we 224 found slightly higher (13%) Ct values in pools, compared to individual tests. Similar findings have been published by other researchers (22). 225 226 This observed slight difference still allows for the safe use of saliva

> pooling for surveillance purposes with sufficient diagnostic accuracy. 227 228 Nevertheless, pooling strategies are described in the latest update of COVID-19 testing strategies and objectives published by the ECDC 229 230 (11). There is evidence of benefits from pooling in low prevalence 231 countries with a low proportion of positive samples – up to 5%. Recent 232 publications indicate that for populations with a prevalence of less than 233 1% the testing of saliva pools of 10 or 20 samples is more beneficial, 234 and our independent calculations also bear this out. Comparing the 235 correlation between different pool sizes (usefulness and efficiency) 236 with test positivity rate, we concluded that a pool size of 10 is more 237 efficient than a pool size of 5. The calculations are based on test price, 238 reimbursement conditions, and the number of tests per sample (when 239 using a pooling strategy) (23,24).

> The pooling strategy for self-collected saliva samples is the optimal 240 241 solution that saves resources and reduces the testing time (25). In our 242 real-life field test on a "perifocal" population, we successfully tested 243 nearly a third of the citizens of the town of Kuldiga in three days. This 244 allowed for fast identification of asymptomatic SARS-CoV-2 cases 245 and those with mild symptoms to enable timely contact tracing and 246 outbreak containment. The use of nasopharyngeal swabs in such a 247 situation would have required more staff and time with possible patient 248 compliance issues.

> Additionally, improvements may reasonably be expected in terms of organizing the distribution of self-sampling kits to patients as well as the logistics of returning the kits to the laboratory that would further increase the usefulness of screening using a pooled testing strategy.

There were some limitations in our study: the size of the cohort of
participants was limited, the selected laboratory-developed RT-PCR
method for evaluation was used, also a lack of multicenter observation.
Future studies extending the cohort are needed to confirm current
findings and provide the implications in clinical practice.

258

259 Conclusions

260 Our findings confirm the stability of SARS-CoV-2 RNA in saliva, 261 showing acceptable performance in terms of specificity and sensitivity at the early stages of infection, and the advantages of testing using a 262 263 pooling strategy in a low prevalence population. Ct values and 264 detected/missing gene information are favorable for the interpretation of the results from several aspects, e.g. epidemiological investigation, 265 determination if the patient is infectious at the current stage, etc. Self-266 sampling makes the procedure faster, safer, and requires fewer 267 268 resources. The targeted distribution of test kits among a population with a known outbreak significantly increased the positivity rate. 269 270 Saliva pool testing on a large scale provides an additional tool to take 271 timely measures and contain outbreaks.

272

273 Ethical aspects

274 The study was approved by the Ethics Committee of the Pauls Stradins

275 Clinical University Hospital (record No 300720-18L).

276

277 Acknowledgments

- We gratefully acknowledge all participants for their commitment to 278
- 279 participate and their time. Special thanks to all trial team members in
- 280 the E.Gulbja Laboratory for their dedication and work which made this
- 281 study possible and Dr. A.Gramatniece for editorial help.

282

283 **Author contributions**

- 284 Gavars D - the conception and design of the study, Gavars M, 285 Perminovs D, and Metla Z - validation of the method and 286 interpretation of the data, Stasulans J, Stana J - patient recruitment and data collection, drafting of the article, Tauckels E - data analysis, 287 288 Gulbis E, and Dumpis U – revising the article critically, final approval 289 of the version to be submitted.
- 290

Transparency declaration 291

- 292 All authors declare that there are no conflicts of interest.
- 293

Funding institution: 294

- 295 Ministry of Education and Science, Republic of Latvia. Funding 296 number: VPP-COVID-2020/1-0008.
- Additional funding was provided by E.Gulbja laboratory. 297

298

299 **References:**

- 300 Rapid Risk Assessment: Coronavirus disease 2019 (COVID-19) 1.
- 301 in the EU/EEA and the UK- ninth update [Internet]. European

302	Centre for Disease Prevention and Control. 2020 [cited 2020 Nov
J02	Control Disease i revention and Control. 2020 Jetted 2020 100


- 303 16]. Available from: https://www.ecdc.europa.eu/en/publications-
- 304 data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-
- 305 pandemic-ninth-update
- 306 2. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in
- 307 suspected human cases [Internet]. [cited 2020 Nov 16]. Available
- 308 from: https://www.who.int/publications-detail-redirect/10665-
- 309 331501
- 310 3. COVID-19: Overcoming supply shortages for diagnostic testing |
- 311 McKinsey [Internet]. [cited 2020 Nov 16]. Available from:
- 312 https://www.mckinsey.com/industries/pharmaceuticals-and-
- 313 medical-products/our-insights/covid-19-overcoming-supply-
- 314 shortages-for-diagnostic-testing#
- 315 4. Jeong HW, Kim S-M, Kim H-S, Kim Y-I, Kim JH, Cho JY, et al.
- Viable SARS-CoV-2 in various specimens from COVID-19
 patients. Clin Microbiol Infect. 2020 Nov;26(11):1520–4.
- 318 5. COVID-19 situation update for the EU/EEA and the UK, as of 16
- November 2020 [Internet]. European Centre for Disease
 Prevention and Control. [cited 2020 Nov 16]. Available from:
 https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea
- 322 6. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal
 323 Swab Specimen. N Engl J Med. 2020 May 28;382(22):e76.
- Fakheran O, Dehghannejad M, Khademi A. Saliva as a diagnostic
 specimen for detection of SARS-CoV-2 in suspected patients: a
 scoping review. Infect Dis Poverty. 2020 Jul 22;9(1):100.
- 8. Hamid H, Khurshid Z, Adanir N, Zafar MS, Zohaib S. COVID-19
- 328 Pandemic and Role of Human Saliva as a Testing Biofluid in
- 329 Point-of-Care Technology. Eur J Dent [Internet]. 2020 Jun 3 [cited

- 330 2020 Nov 16]; Available from: http://www.thieme-
- 331 connect.de/DOI/DOI?10.1055/s-0040-1713020
- 332 9. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et
- al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A
- 334 Meta-Analysis. Front Med. 2020 Aug 4;7:465–465.
- 335 10. Objectives for COVID-19 testing in school settings first update,
- 336 21 August 2020. Tech Rep. 2020;4.
- 337 11. COVID-19 testing strategies and objectives [Internet]. European
- 338 Centre for Disease Prevention and Control. 2020 [cited 2020 Nov
- 339 16]. Available from: https://www.ecdc.europa.eu/en/publications-
- 340 data/covid-19-testing-strategies-and-objectives
- 341 12. Commissioner O of the. Coronavirus (COVID-19) Update: FDA
- 342 Authorizes First Diagnostic Test Using At-Home Collection of
- 343 Saliva Specimens [Internet]. FDA. FDA; 2020 [cited 2020 Nov
- 344 16]. Available from: https://www.fda.gov/news-events/press-
- 345 announcements/coronavirus-covid-19-update-fda-authorizes-
- 346 first-diagnostic-test-using-home-collection-saliva
- 347 13. Rutgers Launches Genetic Testing Service for New Coronavirus |
- 348 Rutgers University [Internet]. [cited 2020 Nov 16]. Available
- 349 from: https://www.rutgers.edu/news/rutgers-launches-genetic350 testing-service-new-coronavirus
- 351 14. Bohn M, Mancini N, Loh P, Wang C-B, Grimmler M, Gramegna
- 352 M, et al. IFCC interim guidelines on molecular testing of SARS-
- 353 CoV-2 infection. Clin Chem Lab Med. 2020 Oct 7;
- 15. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial
 Cells Lining Salivary Gland Ducts Are Early Target Cells of
- 356 Severe Acute Respiratory Syndrome Coronavirus Infection in the

357 Upper Respiratory Tracts of Rhesus Macaques. J Virol. 2011 A	Apr
--	-----

- 358 15;85(8):4025–30.
- 359 16. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential
- 360 Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res.
- 361 2020;99(8):989.
- 362 17. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M,
- 363 Tokuyama M, Vijayakumar P, et al. Saliva or Nasopharyngeal
 364 Swab Specimens for Detection of SARS-CoV-2. N Engl J Med.
 365 2020;4.
- 366 18. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al.
 367 Molecular and serological investigation of 2019-nCoV infected
 368 patients: implication of multiple shedding routes. Emerg Microbes
 369 Infect. 2020 Feb 17;9(1):386–9.
- 19. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C,
 Colson P, et al. Viral RNA load as determined by cell culture as a
 management tool for discharge of SARS-CoV-2 patients from
 infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020
- 374 Apr 27;1–3.
- 20. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R,
 Shrestha L, et al. Comparative Performance of SARS-CoV-2
 Detection Assays Using Seven Different Primer-Probe Sets and
 One Assay Kit. J Clin Microbiol. 2020 26;58(6).
- 21. Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ,
 Fernholz E, et al. Evaluation of Saline, Phosphate-Buffered
 Saline, and Minimum Essential Medium as Potential Alternatives
 to Viral Transport Media for SARS-CoV-2 Testing. McAdam AJ,
- 383 editor. J Clin Microbiol. 2020 May 26;58(6):e00590-20.

384	22.	Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner
385		B, et al. Pooling of samples for testing for SARS-CoV-2 in
386		asymptomatic people. Lancet Infect Dis. 2020 Nov
387		1;20(11):1231–2.
388	23.	Regen F, Eren N, Heuser I, Hellmann-Regen J. A simple approach
389		to optimum pool size for pooled SARS-CoV-2 testing. Int J Infect
390		Dis. 2020 Nov 1;100:324–6.
391	24.	Mutesa L, Ndishimye P, Butera Y, Souopgui J, Uwineza A,
392		Rutayisire R, et al. A pooled testing strategy for identifying
393		SARS-CoV-2 at low prevalence. Nature. 2020 Oct 21;1–8.
394	25.	Fogarty A, Joseph A, Shaw D. Pooled saliva samples for COVID-
395		19 surveillance programme. Lancet Respir Med.
396		2020;8(11):1078–80.
397		



■ NPS - SARS-CoV-2 positive □ Saliva samples - SARS-CoV-2 positive ■ NPS - total ■ Saliva samples - total

Table 1 Run No. 1 on saliva stability measurements of 5 samples collected 2-4h before the first testing

	0 after 8h		after 24h	after 25h	
	1st 14:00	2nd 22:00	3rd 14:00	4th 15:00	
1	Positive	Positive	Positive	Positive	
2	Positive	Positive	Positive	Positive	
3	Positive	W- Positive	Positive	W- Positive	
4	Positive	Positive	Positive	No sample left	
5	Positive	W- Positive	Positive	W- Positive	

Abbreviations: W-Positive - weak positive result, h - hours

Table 2 Run No. 2 on saliva stability serial measurements of two samples collected 2-4h before first testing

	0	after 12h	after 22h	after 22h rep.
	1st 12:00	2nd 00:00	3rd 10:00	4th 10:00
6	W- Positive	Positive	Positive	Positive
Ct	35	36	37	37
7	Positive	Positive	Positive	Positive
Ct	32	33	30	31

Abbreviations: W-Positive - weak positive result, rep. - repeats, h - hours

Table 3 Run No. 3 on saliva repeatability measurements of one sample collected 2 - 4h before the first testing with indicated Ct values

	0	after 3h	after 12h	after 24h	
	1st 11:00	2nd 14:00	3rd 02:00	4th 11:00	
8	Positive	Positive	Positive	Positive	
Ct	34	30	33	35	
8 rep.	Positive	Positive	Positive	Positive	
Ct	34	27	31	35	

Abbreviations: rep. - repeats, h - hours

Table 4 Saliva samples compared to the results of nasopharyngeal/ oropharyngeal swabs

		NPS							
Days after the start of symptoms		0-	-14	15-30		31-70		Asymptomatic	
RT-PCR		Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
Saliva	Positive	18	0	22	3	5	2	5	1
Sunvu	Negative	2	2	12	15	2	11	2	2
Sensitivity %		C	90	64.7		71.4		71.4	
Specificity %		1	00	83.3		84.6		66.7	

Abbreviations: NPS - nasopharyngeal/ oropharyngeal swabs, RT-PCR – real-time polymerase chain reaction